Altre lingue Daewoong Pharmaceutical Co., Ltd

Azioni

A069620

KR7069620003

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 10/05/2024			Variaz. 5gg	Var. 1 gen.
110.700 ^KRW	-1,25%		-0,90%	-5,22%

24/04	Le importazioni coreane di zucchero crollano del 14% per l'aumento dei casi di diabete	MT
15/02	Daewoong Pharmaceutical ottiene l'approvazione per l'impianto di trattamento delle cellule staminali in Indonesia	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	24/04
AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	12/04
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	19/03
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia	15/02
Daewoong Pharmaceutical : and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S.	11/12
Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., Ltd. Announces Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S	11/12
Daewoong Pharmaceutical : Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin	06/12
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA	28/11
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy	07/11
P.T. Selatox Bio Pharma announced that it expects to receive IDR 200 billion in funding from Daewoong Pharmaceutical Co., Ltd	27/10/23
Daewoong Pharmaceutical : announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030	26/10/23
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market	19/10/23
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema	25/09/23
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia	30/08/23
Hyphens Pharma International Limited Announces Successful Registration in Malaysia	30/08/23
Daewoong Pharmaceutical : Initiates Global Export of 'Novel Drug'...Launches 'Fexuprazan' in the Philippines	17/08/23
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Daewoong Pharmaceutical's Nabota Surpasses 600,000 Customers in the US	02/08/23
Daewoong Pharmaceutical : Reports Second Quarter 2023 Financial Results	27/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Daewoong Pharmaceutical Co., Ltd

Azioni

A069620

KR7069620003

Altre lingue

Filtri